GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Windlas Biotech Ltd

Windlas Biotech buyback of 4,70,000 shares at INR 1,000 per share

BUYBACK ● No Immediate Change LOW RISK
📅 Filed on BSE: 27 Apr 2026, 06:33 PM IST  ·  BSE ID: be5e1c59-e14c-4b5b-b40d-ccbf87819146
View Original BSE Filing (PDF)
💡
In Simple Terms
Windlas Biotech is buying back 4,70,000 of its own shares from all shareholders at INR 1,000 each, spending INR 47 Crore total.
🤖 AI Summary
  • Windlas Biotech launched buyback of 4,70,000 equity shares at INR 1,000 per share
  • Buyback represents 2.23% of total equity share capital via proportionate tender offer
  • Record Date: April 24, 2026; Letter of Offer dispatched by April 28, 2026
  • Total buyback value INR 47 Crore; Manager: Fintellectual Corporate Advisors Private Limited
🔢 Key Numbers — exact figures from BSE filing, not rounded
Equity shares to be bought back
4,70,000 (Four Lakh Seventy Thousand)
Buyback price per share
INR 1,000
Face value per share
INR 5
Percentage of total equity
2.23%
Total buyback consideration
INR 47 Crore
Record Date
April 24, 2026
🏢 How This Affects the Company
💰
Financial Impact
Buyback will reduce equity share capital by 4,70,000 shares (2.23%) and deploy INR 47 Crore in cash. This reduces total shares outstanding and increases EPS on remaining shares.
👥 What This Means For Shareholders
✅
Action Required
Eligible shareholders must submit tender forms by the specified deadline; forms available on company website www.windlas.com and through stock brokers.
👤
Who Is Affected
All registered equity shareholders and beneficial owners as on Record Date April 24, 2026. Participation is voluntary on proportionate basis; non-tendering shareholders retain their holdings.
🔍
Management Signal
Buyback signals management confidence in intrinsic value and intent to optimize capital structure by reducing equity base.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Tender offer closure date — confirm deadline for share submission by shareholders
Buyback completion filing — track Reg 30 disclosure confirming execution of all tendered shares
Updated shareholding pattern — monitor promoter and public shareholding post-buyback completion
LOW RISK Buyback conducted under SEBI (Buy-back of Securities) Regulations 2018 with clear proportionate terms, established timeline, and professional intermediaries. No operational or liquidity risk signaled.
💡 Investor Takeaway
Windlas Biotech is repurchasing 4,70,000 shares (2.23% of equity) at INR 1,000 per share for total INR 47 Crore. All shareholders as of April 24, 2026 are eligible to participate on proportionate basis via tender offer.
⚖️ Strengths & Concerns

✅ Positives

  • Proportionate tender offer ensures all eligible shareholders participate equitably in buyback.
  • Clear timeline with Record Date established (April 24, 2026) and dispatch by April 28, 2026.

⚠️ Concerns

  • Buyback deploys INR 47 Crore capital that could be retained for growth or debt reduction.
  • Filing does not disclose rationale or timing justification for the buyback decision.
📅 Company Track Record
Board approved buyback on April 17, 2026 (intimated April 14, 2026). Public announcement made April 18, 2026, published April 20, 2026. Letter of Offer submitted April 27, 2026. This is the first formally detailed buyback disclosure for Windlas Biotech.

Based on publicly available historical data. For context only.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.